Pharmena S.A. (WSE:PHR)

Market Cap	32.19M -13.7%
Revenue (ttm)	1.46M +64.3%
Net Income	-3.06M
EPS	-0.27
Shares Out	11.14M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	132
Open	2.820
Previous Close	2.890
Day's Range	2.820 - 2.890
52-Week Range	2.500 - 4.320
Beta	0.48
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 27, 2026

About Pharmena

Pharmena S.A. engages in the sale of dietary supplements in Poland and internationally. The company also develops 1-MNA (PHR-701 program), a medical device for use in difficult-to-heal wounds. In addition, it is involved in research and development of therapeutic applications of 1 MNA as an anti-inflammatory and anti-fibrotic drug; and research and development at pulmonary fibrosis, respiratory tract infections, including viral infections, COVID-19, inflammatory diseases, metabolic diseases and other therapeutic applications. The company was in...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 7
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: PHR

Financial Performance

In 2025, Pharmena's revenue was 1.58 million, an increase of 488.43% compared to the previous year's 268,000. Losses were -2.77 million, 119.4% more than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 4, 2026

Data Sources Report a data error